Recombinant Mouse CD279/PDCD1/PD1 Protein, C-His (PX-P6064) expressed in Mammalian Cells, Purity: >90% as determined by SDS-PAGE..
Highlights
High Purity (>90% as determined by SDS-PAGE.) — Verified by SDS-PAGE for downstream accuracy.
Mammalian Cells Expression — Optimized for functional studies.
表达系统
Mammalian Cells
Accession号
Q02242
蛋白长度
Met1-Gln167
应用
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
种属
Mus musculus (Mouse)
性质
Recombinant
内毒素水平
Please contact with the lab for this information.
纯度
>90% as determined by SDS-PAGE.
预测分子量
20.09 kDa
状态
Lyophilized
保存溶液
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
重悬
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
运输
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名
Programmed cell death protein 1, Protein PD-1, mPD-1, CD279, Pdcd1, Pd1
背景
Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands, such as CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo).
1. Nishimura, H. et al. (1999) Immunity 11, 141-51. PMID: 10485649
2. Nishimura, H. et al. (2001) Science (New York, N.Y.) 291, 319-22. PMID: 11209085
3. Okazaki, T. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 13866-71. PMID: 11698646
4. Okazaki, T. et al. (2011) The Journal of experimental medicine 208, 395-407. PMID: 21300912
5. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443
6. Latchman, Y. et al. (2001) Nature immunology 2, 261-8. PMID: 11224527
7. Lin, DY. et al. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 3011-6. PMID: 18287011
8. Lázár-Molnár, E. et al. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 10483-8. PMID: 18641123
9. Yokosuka, T. et al. (2012) The Journal of experimental medicine 209, 1201-17. PMID: 22641383
